Colorado Center for AIDS Research at the University of Colorado Denver
  • Home
  • Faculty
  • Education
  • Fellowship
  • Research
  • Clinical Programs
  • Tim Gill Endowment
  • Colorado IDSA
  • ACTU
  • CFAR
  • IDGP
  • History
  • Links

UCD Links

  • UCD
  • School of Medicine
  • Department of Medicine
UCD Site Index
A B C D E F G
H I J K L M N
O P Q R S T U
V W X Y Z    
UCD Search

 

Mary Bessesen, M.D.

Associate Professor of Medicine

Chief, Infectious Diseases, DVAMC

 

 

Phone:       303-393-2837
E-mail:
       Mary.Bessesen@uchsc.edu
Address:   Denver Veteran's Administration Medical Center

                     Infectious Disease (111L)
                     1055 Clermont St
                     Denver, CO 80220

 

   Medical School

University of Kansas
Residency
University of Colorado
Fellowship
University of Colorado
Research Interests
Dr. Bessesen serves as Section Head of the Division at the Denver Department of Veterans Affairs Medical Center. She directs the care of over 300 HIV- 1 infected individuals at the VAMC and has completed projects investigating prophylaxis of Pneumocystis jiroveci pneumonia, describing the role of Mycobacterium genavense as a pathogen in advanced HIV disease and demonstrating the cost-effectiveness of antiretroviral therapy. She also supervises the Infection Control program at the Veterans Eastern Colorado Health Care System and is pursuing research interests in Staphylococcus aureus carriage, invasive disease and control measures, and Clostridium difficile disease.

Selected Publications

  1. Bessesen MT, Shlay JT, Stone-Venohr B, Cohn DL, Reves RR. Disseminated Mycobacterium genavense infection in AIDS: Clinical and microbiological features and response to therapy. AIDS, 7:1357-61, 1993
  2. Pechere M, Opravil M, Wald A, Chave JP, Bessesen M, Sievers A, Hein R, von Overbeck J, Clark RA, Tortoli E, Emler S, Kirschner P, Gabriel V, Bottger E, Hirschel B, the Swiss HIV Cohort Study. Clinical and epidemiologic features of infection with Mycobacterium genavense. Arch Intern Med, 155:400-404, 1995.
  3. Bessesen MT, Miller LA, Cohn DL, Bartlett S, Ellison RT. Pharmacokinetics and toxicity of fansidar in the prophylaxis of Pneumocystis carinii pneumonia in AIDS. Clinical Infectious Diseases, 20:730-1, 1995
  4. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in HIV-infected patients following development of resistance to or withdrawal of lamivudine. Clinical Infectious Diseases, 28:1032-5, 1999
  5. Koeppe J., Belknap R., Bessesen M. Mycobacterium avium complex peritonitis in the setting of cirrhosis. Scandinavian Journal of Infectious Disease, 36:615-7, 2004
  6. Wyles D, Weinberg, A, Bessesen M, Madinger N, Schooley R. Development of Herpes Simplex Virus Disease in Patients Receiving Cidofovir, Clin Infect Diseases, 41:676-80 2005, Epub 2005 Jul 26
  7. Bessesen MT. Toxic Shock Syndrome In Critical Care Secrets, ed PE Parsons, JP Weiner-Kronish. Hanley & Belfus, Philadelphia, 1998
  8. Bessesen MT. Life-Threatening Community-Acquired Infections: Toxic Shock Syndrome, Overwhelming Postsplenectomy Infection, Meningococcemia, Malaria, Rocky Mountain Spotted Fever, and Others; In Irwin & Rippe's Intensive Care Medicine. Lippincott Williams & Wilkins, York, Pennsylvania, 2006

Division of Infectious Diseases
12700 E. 19th Avenue, B168
Aurora, CO 80045

Phone 303 724 4922

Fax 303 724 4926